Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ozuriftamab vedotin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BioAtla
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Ozuriftamab vedotin + pembrolizumab** is an experimental **combination therapy** composed of ozuriftamab vedotin (CAB-ROR2-ADC), a conditionally active biologic antibody-drug conjugate (ADC) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), and pembrolizumab, a programmed death 1 (PD-1) immune checkpoint inhibitor. Ozuriftamab vedotin delivers a microtubule-disrupting agent to ROR2-expressing tumor cells, while pembrolizumab blocks PD-1, enhancing anti-tumor immune responses. This combination is under clinical investigation for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in patients previously treated with anti–PD-1/PD-L1 therapies, with ongoing trials indicating promising efficacy and manageable safety[1][7][8][9].
- Other names
- ozuriftamab vedotinKeytruda
02
Targets
ROR2PDCD1 (Programmed cell death protein 1 receptor)Microtubule
Beyond the preview
Go deeper on ozuriftamab vedotin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ozuriftamab vedotin + pembrolizumab.